Related references
Note: Only part of the references are listed.Milestones in the treatment of hepatocellular carcinoma: A systematic review.
Maciej Gryziak et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review
Francesca Matilde Schipilliti et al.
PHARMACEUTICALS (2021)
Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer
Sundee Dees et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka et al.
ONCOLOGY (2019)
Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies
Moo-Kon Song et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer
Steven Feins et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy
Marion Subklewe et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2019)
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
E. Liu et al.
LEUKEMIA (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms
Kirstie L. S. Cleary et al.
JOURNAL OF IMMUNOLOGY (2017)
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape (Publication with Expression of Concern. See vol. 129, pg. 3464, 2019)
Meenakshi Hegde et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells (vol 4, pg 498, 2016)
Eugenia Zah et al.
CANCER IMMUNOLOGY RESEARCH (2016)
The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
Michael Hudecek et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
Huiping Gao et al.
CLINICAL CANCER RESEARCH (2014)
Glypican-3 antibodies: A new therapeutic target for liver cancer
Mingqian Feng et al.
FEBS LETTERS (2014)
The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia
Kaat Durinck et al.
HAEMATOLOGICA (2014)
Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects
Huan Shi et al.
MOLECULAR CANCER (2014)
First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma
Andrew X. Zhu et al.
CLINICAL CANCER RESEARCH (2013)
Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA
Marie-Helene Delfau-Larue et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation
Yu-Liang Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy
Carlos A. Ramos et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Next-generation sequencing identifies the natural killer cell microRNA transcriptome
Todd A. Fehniger et al.
GENOME RESEARCH (2010)
Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers
Pisit Tangkijvanich et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2010)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Glypican-3: From the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma
Baruch D. Jakubovic et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2007)
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR zeta/CD28 receptor
J Maher et al.
NATURE BIOTECHNOLOGY (2002)